<?xml version="1.0" encoding="UTF-8"?>
<p>A total of 7 SHARED‐2 participants (12%; 95% CI: 4, 20; Fig. 
 <xref rid="hep41482-fig-0002" ref-type="fig">2</xref>) experienced grade 3 AEs, similar to the 13% (95% CI: 9, 18) of SHARED‐1 participants who experienced grade 3 or 4 AEs. There were no grade 4 AEs or deaths in SHARED‐2 participants during the study. The grade 3 AEs among SHARED‐2 participants consisted of hypertension (6), insomnia (1), weakness (1), and hyperglycemia (1) with none of the AEs judged to be related to the study drug.
</p>
